Literature DB >> 2712711

Hypolipemic activity of K12.148 in rats, marmosets and pigs.

M Schliack1, R Löser, K Seibel, K H Blay.   

Abstract

The hypolipemic effect of K12.148, a new hypolipemic compound, was examined in normolipemic rats, marmosets and pigs. It could be demonstrated that this compound reduced serum lipids, and in particular serum cholesterol, very effectively in all tested animal species. The analysis of the lipids of the pig give evidence that the hypocholesterolemic effect is due to a reduction of LDL only. In vitro experiments with rat liver homogenates suggest that the hypocholesterolemic effect is brought about by the inhibition of hepatic cholesterol synthesis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2712711

Source DB:  PubMed          Journal:  Artery        ISSN: 0098-6127


  3 in total

1.  Clinical pharmacology of the hypocholesterolemic agent K 12.148 (lifibrol) in healthy volunteers.

Authors:  H Hasibeder; H J Staab; K Seibel; B Heibel; G Schmidle; W März
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Safety and efficacy of lifibrol upon four-week administration to patients with primary hypercholesterolaemia.

Authors:  P Schwandt; R Elsässer; C Schmidt; B Gertz; M Heil; J Augustin; K Seibel
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

3.  Action of the new hypolipidemic agent lifibrol (K12.148) on lipid homeostasis in normal rats: plasma lipids, hepatic sterologenesis, and the fate of injected [14C]acetate.

Authors:  F P Bell; L C St John
Journal:  Lipids       Date:  1993-12       Impact factor: 1.880

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.